2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Bacterial, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4450 Aspirin versus anticoagulation for venous thromboembolism prophylaxis after surgical management of traumatic hip fracture

Collin Knudson, Whitney Quast, MS2, JB Breeding, PharmD, BCPS3, Jennifer Osborn, PharmD4, Brady Baartman, PA-C5, Todd De For, MS6, Ariela Marshall, MD7, Jacob C. Cogan, MD8
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 University of Minnesota, Minneapolis, Minnesota, United States
5 University of Minnesota, Minneapolis, Minnesota, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 University of Minnesota, Minneapolis, Minnesota, United States

Introduction

Growing literature supporting aspirin (ASA) as effective prophylaxis against postoperative venous thromboembolism (VTE) in orthopedic surgery has driven widespread clinical use. However, ASA may be insufficient after high VTE risk surgeries such as traumatic hip fracture repair (THFR). In this study, we sought to evaluate the rates of VTE after hospitalization for THFR in patients managed with either ASA or anticoagulation (AC) for prophylaxis.  

Methods

In this retrospective review of electronic medical record data from a statewide health system in Minnesota, we identified patients who underwent THFR between 2022 and 2024. The primary endpoint was imaging-confirmed VTE within 30 days after hospitalization for THFR. Secondary endpoints were bleeding requiring readmission, readmission for any reason, reoperation, or death within 30 days after hospitalization. Patients with VTE after surgery but prior to discharge and those with active cancer were excluded. VTE was estimated using cumulative incidence with 95% confidence intervals (95% CI) treating non-VTE mortality as a competing risk. Gray’s test was used to complete the comparisons. Fine and Gray regression was used to estimate hazard ratios. Secondary endpoints were estimated with simple proportions along with Exact 95% CI. Logistic regression was used to examine the odds ratio of ASA vs AC. Cox regression was used to estimate the hazard ratio between groups.

Results

We identified 1,632 patients who underwent THFR, of which 1,294 (79%) received ASA as VTE prophylaxis and 338 (21%) received AC. The median age was 80, and 69% of patients were female. Surgeries included open reduction internal fixation (49%), hemiarthroplasty (26%), total arthroplasty (19%), and closed reduction (6%). There were 30 patients who developed a post-operative VTE within 30 days after discharge (1.8% (95% CI 0.1-2.6%)). Of these, 28 were on ASA for VTE prophylaxis versus 2 on AC prophylaxis (cumulative incidence 2.2% (0.1-3.1%) for ASA vs. 0.6% (0.01-2.0%) for AC, p = 0.06). The hazard ratio for VTE in patients on ASA prophylaxis relative to AC prophylaxis was 3.7 (0.9-15.5, p = 0.08). Regarding secondary outcomes, 17 patients experienced bleeding requiring readmission (1.0% (0.06-1.7%)). Of these, 15 were on ASA versus 2 on AC (1.2% (0.7-1.9%) for ASA vs. 0.6% (0.0-1.4%) for AC, p = 0.55). The odds ratio for bleeding on ASA relative to AC was 2.0 (0.5-8.7, p = 0.37). There were no significant differences between ASA and AC in rates of readmission, reoperation, and death.

Conclusion

In this retrospective review of 1,632 THFRs over 3 years, there was no statistically significant difference between ASA and AC prophylaxis in rates of postoperative VTE and bleeding. However, based on the actual number of VTE events in both groups, a larger sample may have shown a significant difference in favor of AC from both an effectiveness as well as a safety standpoint. Follow up studies are planned in this and other surgical populations to better evaluate appropriate prophylaxis strategies.

Jacob C. Cogan, MD: No relevant conflicts of interest to declare.